Condie Carmack 
Eli Lilly and Co. gained more oomph in its weight-loss battle with Novo Nordisk A/S, as the firm highlighted another batch of results from Surmount-5, a phase IIIb open-label trial evaluating the safety and efficacy of Zepbound (tirzepatide), a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor agonist compared to the Novo prospect Wegovy … Read more
In a a juxtaposition of events that redefines the meaning of “coincidence,” President Trump announced a new policy for prescription drug pricing this morning, and the the Spring 2025 issue of the Journal of Economic Perspectives, released three days ago on Friday morning, begins with a four-paper symposium on drug pricing. (Full disclosure: I work … Read more
President Donald Trump signed an executive order May 12 directing drugmakers to sell medicines in the U.S. at prices similar to those offered in other wealthy countries, or face penalties and enforcement actions. The move tasks HHS Secretary Robert F. Kennedy Jr. with setting target prices to bring U.S. drug costs “in line with comparably … Read more
President Donald Trump signed an executive order on Monday aimed at slashing prescription drug prices in the U.S. that could lead to the capping of prices at a level equivalent to the cost in similar nations. The U.S. has paid more than other similarly wealthy countries for prescription drugs for decades, with a 2024 study conducted … Read more
For years, researchers had been searching for hormones that promote insulin secretion. These hormones, known as incretins, could be the key to helping treat type 2 diabetes (T2D). In the 1980s, glucagon-like peptide-1 (GLP-1) was found to be an incretin secreted by L-cells in the small intestine and to inhibit glucagon secretion. However, because of … Read more
Eli Lilly’s GLP-1 drug Zepbound helped nearly 25 percent more participants lose weight than Novo Nordisk’s Wegovy, according to the trial results.
MONDAY, May 12, 2025 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in Diabetes, Obesity and Metabolism and presented at the annual meeting of…
A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy.
New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the journal eClinicalMedicine finds that first-generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.
In an erratic soliloquy before he signed an executive order to bring down the price of prescription drugs, President Donald Trump took aim at the “fat shot drug” he said was an example of how Big Pharma inflates the cost of medications. Trump was presumably talking about the popular GLP-1 drugs on the market under … Read more